Half Moon Medical has announced the treatment of 15 patients with its second generation Half Moon transcatheter mitral valve repair (TMVR) technology as part of an ongoing pilot study.
The investigational Half Moon mitral valve repair device is designed to restore mitral valve function in patients with severe symptomatic mitral regurgitation (MR).
The device is deployed using a percutaneous delivery catheter, which is navigated through the vasculature to the diseased native mitral valve. The Half Moon device has been shown to produce significant, sustained reduction in MR without an increase in pressure gradient across the valve in a wide range of valve anatomies not addressable by other percutaneous therapies, Half Moon Medical said in a press release.
Interventional cardiologists in the USA and Australia have implanted the Half Moon device in the ongoing pilot study.
“The Half Moon device allowed us to successfully treat a patient with severe mitral regurgitation who had no other meaningful treatment options. We are very excited about the opportunity to expand our percutaneous toolbox for the treatment of mitral valve disease,” said Stan Chetcuti (University of Michigan, Ann Arbor, USA) who treated the 15th patient with the second-generation Half Moon device along with his team consisting of Neal Duggal, director of anaesthesia for structural heart interventions, and Matthew Romano, associate professor of cardiac surgery.
Two physician-led presentations highlighting the Half Moon device will be featured at New York Valves (5–7 June, New York, USA). Azeem Latib (Montefiore Health System, New York, USA) will be presenting interim data from the Half Moon pilot study and Hemal Gada (UPMC Heart and Vascular Institute, Harrisburg, USA) will present a case performed using the Half Moon device in a patient with complex mitral valve pathology that could not be addressed by transcatheter edge to edge repair (TEER) or TMVR.
“We are encouraged by the promising results we have seen to-date with the Gen 2 Half Moon device significantly reducing mitral regurgitation in a wide range of challenging anatomies,” said Matt McLean, CEO and co-founder of Half Moon Medical. “We are also thankful to our physician partners who are bringing this innovative therapy to patients in need.”
